Showing 8691-8700 of 9994 results for "".
- Pacific Edge Granted US Patent for Melanoma Detectionhttps://practicaldermatology.com/news/20140905-pacific_edge_granted_us_patent_for_melanoma_detection/2459127/The United States Patent and Trademark Office granted Pacific Edge Limited, a cancer diagnostics company, US Patent Number 8,822,149 covering "Prognosis Prediction for Melanoma Cancer." The patent covers the technology being used to develop a melanoma prognostic test that will e
- Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirushttps://practicaldermatology.com/news/20140903-novan_to_present_antiviral_preclinical_results_of_nitric_oxide-releasing_drug_candidates_for_the_treatment_of_papillomavirus/2459131/Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, will present antiviral data from a preclinical animal study at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ta
- Modernizing Medicine Announces Inaugural EMA Nation Users Conferencehttps://practicaldermatology.com/news/20140903-modernizing_medicine_announces_inaugural_ema_nation_users_conference/2459133/Modernizing Medicine, Inc., creator of the Electronic Medical Assistant (EMA), announces its inaugural EMA Nation Users Conference. The conference will provide a venue for users of this specialty-specific electronic health record (EHR) system to network and learn how to use EMA's expanding capabilit
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce
- Justin Chickles Joins myoscience as Vice President of Commercial Development & Johanna Beckmen Becomes General Manager of Aestheticshttps://practicaldermatology.com/news/20140812-justin_chickles_joins_myoscience_as_vice_president_of_commercial_development__johanna_beckmen_becomes_general_manager_of_aesthetics/2459148/Justin Chickles is now Vice President of Commercial Development and Johanna Beckmen is now promoted to General Manager of Aesthetics of Myoscience, Inc. Chickles Said, "Myoscience's ioveradegrees treatment is poised to become a transformative therapy for patients living with pain.The pas
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bu
- Cynosure Appoints Timothy W. Baker as Presidenthttps://practicaldermatology.com/news/20140730-cynosure_appoints_timothy_w_baker_as_president/2459154/The Board of Directors of Cynosure, Inc., which develops and markets laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to Presi
- FDA Approves of Acticlate Tablets from Aqua Pharmaceuticals, LLChttps://practicaldermatology.com/news/20140728-aqua_pharmaceuticals_llc_announces_fda_approval_of_acticlate_tablets/2459155/The FDA approved Aqua Pharmaceuticals' Acticlate (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, an oral antibiotics for acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.
- Psoriasis Foundation Awards 13 Research Fellowshipshttps://practicaldermatology.com/news/20140721-psoriasis_foundation_awards_13_research_fellowships/2459162/The National Psoriasis Foundation awarded 13 residents and medical students each a one-year, $50,000 fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study
- Benefits of Multi-beam OCT Presented at the 24th Annual Education Week for Practical Dermatology and Venereologyhttps://practicaldermatology.com/news/20140718-benefits_of_multi-beam_oct_presented_at_the_24th_annual_education_week_for_practical_dermatology_and_venereology/2459164/Michelson Diagnostics, a UK based medical device company, announced that a session on the benefits of the multi-beam OTC —"Evidence for OCT diagnostics" — will be presented during the 24th Annual Education Week for Practical Dermatology and Venereology, known as Fortbildungswoche, in Munich, Germ